HCV co-infection significantly impacts on inflammation, endothelial activation and coagulation function parameters leading to several comorbidities among people living with HIV (PLWH). The new direct-acting antivirals (DAAs) therapy achieves eradication of HCV in the majority of patients. However, the early effect of HCV eradication on these parameters on PLWH has been scarcely explored. We have analyzed the effect of HCV on systemic inflammation and endothelial/coagulation function in PLWH and its evolution after HCV eradication with DAAs.
Twenty five HIV/HCV coinfected (HIV/HCV group),25 HIV-infected (HIV group) and 20 healthy controls (HC) were included. All patients were on ART and HIV suppressed. Parameters of systemic inflammation, endothelial activation and coagulation were measured on plasma samples using Human Custom ProcartaPlex kit (Invitrogen,Thermo Fisher Scientific) and acquired on a Luminex analyzer (Bio-Plex 200 System by Biorad). Cross-sectional and longitudinal (comparing baseline vs 12 weeks after end of treatment in HIV/HCV group) analyses were performed. Non-parametric tests were used to establish inter and intra-group differences.
No significant differences between HIV and HC groups were observed for any of the parameters analyzed. In contrast, at baseline HCV/HIV group showed increased levels of IL-18 (p=0.028), IP-10 (p<0.0001), VCAM-1 (p<0.0001) and ICAM-1 (p=0.045) compared to HC and HIV groups. Interestingly, the highest levels of these markers were observed in HCV/HIV patients with significant liver fibrosis (>F2, n=10), with significant differences between <F2 and >F2 HIV/HCV patients for IL18 and IP10 (p=0.007 and p=0.015, respectively). Of note, after HCV eradication, levels of VCAM-1 remained significantly increased compared to HIV and HC groups (p=0.006) with a similar profile in patients with (>F2) and without (<F2) liver fibrosis (p=0.034 and p=0.033 respectively), whereas levels of IP-10 remained significantly increased only in patients with liver fibrosis (p=0.032).
Both HCV co-infection and presence of liver fibrosis significantly impacts on markers of systemic inflammation and endothelial activation in PLWH. Normalization of these parameters is not completely achieved after HCV eradication, especially in patients with liver fibrosis. These data prompts HCV treatment in all HIV/HCV coinfected patients at the earliest stages of liver damage to enhance normalization of systemic inflammation and endothelial activation.